In a refrigerator at 2C8C
Need for more studies The other largest consistency seen across all articles is the call for more large-scale, high-quality studies to be done on this topic
[1] Licensed pharmacological options in the UK include orlistat (available at BMI 30 kg/m, or 28 kg/m with weight-related risk factors) and semaglutide (available within specialist weight management services as per NICE TA875, with adjusted BMI thresholds for some ethnic groups)
But what the generic industry has done also, with regards to sterile injectable of these very complex drugs is push these generic medicines that have been around for a long time, their price is so low that the manufacturers are technically not making any money
The pooled GLP1-RA analysis demonstrated benefits in the secondary endpoints as well, with a 13% reduction in cardiovascular death [HR, 0.87 (0.800.94)], 10% reduction in MI [HR, 0.90 (0.830.98)], 17% reduction in stroke [HR, 0.83 (0.760.92)], 11% reduction in heart failure hospitalizations [HR, 0.89 (0.820.98)], and 12% reduction in all-cause mortality [HR, 0.88 (0.820.94)] [26]
